Genotyping of patients with neuroblastoma treated with dinutuximab, GM-CSF, IL-2, and isotretinoin revealed that certain inhibitory KIR/KIR ligand genotypes had better event-free survival (EFS) and OS, but those with KIR ligand missing for their inhibitory KIRs did not show benefit with immunotherapy over isotretinoin alone [166]. The gene discussed is IL2; the disease is neuroblastoma.